Abetalipoproteinemia

Known as: Acanthocytosis, MTP DEFICIENCY, Microsomal Triglyceride Transfer Protein Deficiency Disease 
An autosomal recessive disorder of lipid metabolism. It is caused by mutation of the microsomal triglyceride transfer protein that catalyzes the… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Mutations in the kinase domain (KD) of BCR-ABL are the most prevalent mechanism of acquired imatinib resistance in patients with… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Is this relevant?
Highly Cited
2005
Highly Cited
2005
The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute… (More)
Is this relevant?
Review
2005
Review
2005
Imatinib, a potent inhibitor of the oncogenic tyrosine kinase BCR–ABL, has shown remarkable clinical activity in patients with… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Resistance to the ABL kinase inhibitor imatinib (STI571 or Gleevec) in chronic myeloid leukemia (CML) occurs through selection… (More)
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Clinical studies have shown that the tyrosine kinase inhibitor STI571 effectively controls BCR-ABL-positive chronic myelogenous… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Through sequencing analysis of blood or bone marrow samples from patients with chronic myeloid leukemia, we identified BCR-ABL… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Selective inhibition of the BCR-ABL tyrosine kinase by imatinib (STI571, Glivec/Gleevec) is a promising new therapeutic strategy… (More)
  • table 1
  • table 2
  • table 4
  • figure 2
  • figure 1
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Targeting the tyrosine kinase activity of BCR-ABL represents a very promising therapeutic strategy in chronic myeloid leukemia… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?
Highly Cited
1997
Highly Cited
1997
The BCR/ABL oncogenic tyrosine kinase activates phosphatidylinositol 3-kinase (PI-3k) by a mechanism that requires binding of BCR… (More)
Is this relevant?
Highly Cited
1992
Highly Cited
1992
Abetalipoproteinemia is a human genetic disease that is characterized by a defect in the assembly or secretion of plasma very low… (More)
Is this relevant?